Publications Database

Accordino R. E. et al. (2016)

Psychopharmacological interventions in autism spectrum disorder.

Expert Opinion on Pharmacotherapy

May, 17(7), pp. 937-952.

Read Abstract (New Window)

Alaghband-Rad J. et al. (2013)

Memantine induced speech problem in two patients with autistic disorder.

Daru

21(1), pp. 54

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2017)

Safety and efficacy of memantine in children with autism: Randomized, placebo-controlled study and open-label extension.

Journal of Child and Adolescent Psychopharmacology

June, 27(5), pp. 403-412.

Read Abstract (New Window) Read Full (New Window)

Aman M. G. , Hollway J. A. , Arnold L. E. (2008)

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 713-738

Read Abstract (New Window)

Chez M. G. et al. (2007)

Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.

Journal of Child Neurology

22(5), pp. 574-579

Read Abstract (New Window)

Doyle C. A. , McDougle C. J. (2012)

Pharmacotherapy to control behavioral symptoms in children with autism.

Expert Opinion on Pharmacotherapy

13(11), pp. 1615-1629.

Read Abstract (New Window)

Eissa N. et al.

Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder.

Frontiers in Neuroscience

Read Full (New Window)

Erickson C. A. et al. (2007)

A retrospective study of memantine in children and adolescents with pervasive developmental disorders.

Psychopharmacology (Berl)

191(1), pp. 141-147

Read Abstract (New Window)

Erickson C. A. , Chambers J. (2006)

Memantine for disruptive behavior in autistic disorder.

Journal of Clinical Psychiatry

67(6), pp. 1000

Erickson C. A. , Mullett J. E. , McDougle C. J. (2009)

Open-label memantine in fragile X syndrome.

Journal of Autism and Developmental Disorders

39(12), pp. 1629-1635.

Read Abstract (New Window)

Ghaleiha A. et al. (2013)

Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

International Journal of Neuropsycholpharmacology

16(4), pp. 783-789.

Read Abstract (New Window)

Ghanizadeh A. (2011)

Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment.

Neurochemical Research

36(5), pp. 922-923.

Read Abstract (New Window)

Joshi G. et al. (2016)

A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder.

Journal of Psychopharmacology

June, 36(3), pp. 262-271.

Read Abstract (New Window)

King B. H. et al. (2001)

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

40(6), pp. 658-665

Read Abstract (New Window)

Kumar B. et al. (2012)

Drug therapy in autism: a present and future perspective.

Pharmacological Reports

64(6), pp. 1291-1304.

Read Abstract (New Window) Read Full (New Window)

Lee Y. J. et al. (2014)

Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

Clinical Psychopharmacology and Neuroscience

Read Abstract (New Window) Read Full (New Window)

Mohammadi M. et al. (2013)

Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.

Clinical Neuropharmacology

36(6), pp. 179-184.

Read Abstract (New Window)

Niederhofer H. (2007)

Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism.

Journal of Clinical Psychopharmacology

27(3), pp. 317-318

Nikvarz N. N. et al. (2017)

Comparing efficacy and side effects of memantine vs. risperidone in the treatment of autistic disorder.

Pharmacopsychiatry

January, 50(1), pp. 19-25.

Read Abstract (New Window)

Owley T. et al. (2006)

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 517-552

Read Abstract (New Window)